NCT06016972View on ClinicalTrials.gov

Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

March 5, 2024

Primary Completion Date

August 20, 2024

Study Completion Date

August 20, 2024

Conditions
Primary Open Angle Glaucoma (POAG)Primary Open Angle Glaucoma of Both EyesPrimary Open-Angle Glaucoma, Unspecified EyeOcular Hypertension (OHT)
Interventions
DRUG

Experimental: QLS-111 ophthalmic solution, (0.015%)

QLS-111 ophthalmic solution, (0.015%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.

DRUG

Experimental: QLS-111 ophthalmic solution, (0.03%)

QLS-111 ophthalmic solution, (0.03%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.

DRUG

Experimental: QLS-111 ophthalmic solution, (0.075%)

QLS-111 ophthalmic solution, (0.075%) applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.

OTHER

QLS-111 ophthalmic vehicle solution

Vehicle ophthalmic solution applied QAM OU for 7 days followed by QPM dosing OU for 7 days, and BID OU dosing for 7 days to constitute a 21-day study treatment period. All IP for this study will be supplied masked in PF single use vials.

Trial Locations (1)

30076

Coastal Research Associates, LLC, Roswell

All Listed Sponsors
lead

Qlaris Bio, Inc.

INDUSTRY

NCT06016972 - Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients | Biotech Hunter | Biotech Hunter